The purpose of this study is to evaluate the change in signs of inflammation/local infection when Mepilex Border Ag is used in normal clinical practice when used on chronic ulcers (venous leg, diabetic foot and pressure ulcers) and partial thickness burns in need\* of topical antimicrobial treatment according to the physician.
The investigation is designed as an open, non-controlled, post-marketing clinical follow-up. Subjects with chronic ulcers or partial thickness burns (including donor sites) at 2 sites will be included. Each subject with a chronic ulcer will be seen once a week for a maximum of 4 weeks or until desired treatment effect is obtained, whichever occurs earlier. Each subject with a partial thickness burn/donor site will be followed once a week for a maximum of 3 weeks or until desired treatment effect is obtained, whichever occurs earlier. All dressing changes will be done according to clinical routine practices and will follow IFU (instruction for use)
Study Type
INTERVENTIONAL
Allocation
NA
Purpose
TREATMENT
Masking
NONE
Enrollment
27
Mepilex Border Ag may be left in place for up to seven days, depending on the condition.
Institute for advanced wound care
Momtgomery, Alabama, United States
Burn treatment center
Iowa City, Iowa, United States
Center for Curative & Palliative Care, Calvary Hospital
The Bronx, New York, United States
Wound Are at Baseline
Time frame: Baseline
Wound Area at Visit 2
At each visit the wound length and width is measured and calculated in cm2.
Time frame: After one week
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.